Abstract
The overall objective of this CRP is to develop radiopharmaceuticals for targeted therapy using {sup 188}Re and {sup 90}Y and to study the performance of generators with long lived parent radionuclides as well as to validate the QC control procedures for estimating the purity of generator eluents. The CRP is expected to enhance the capability in production of {sup 90}Y and {sup 188}Re radiopharmaceuticals to meet the increasing demand of therapeutic products for clinical applications, in particular in Brazil. In this period efforts were made towards the assembling of {sup 90}Sr-{sup 90}Y generators, quality control of {sup 90}Y, the labelling of DMSA(V) and anti-CD20 with {sup 188}Re and the labelling of Hydroxiapatite(HA) with {sup 90}Y. (author)
Osso, Jr., J. A.;
Barrio, G.;
Dias, C. R.B.R.;
Brambilla, T. P.;
Dantas, D. M.;
Suzuki, K. N.;
Barboza, M. F.S.;
Bortoleti, E.;
Fukumori, N. T.;
Mengatti, J.
[1]
- Radiopharmacy Center – Institute of Energetic and Nuclear Research – IPE N-CNEN/SP, São Paulo – Brazil (Brazil)
Citation Formats
Osso, Jr., J. A., Barrio, G., Dias, C. R.B.R., Brambilla, T. P., Dantas, D. M., Suzuki, K. N., Barboza, M. F.S., Bortoleti, E., Fukumori, N. T., and Mengatti, J.
Country report: Brazil. Development of Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide Therapy at IPEN-CNEN/SP.
IAEA: N. p.,
2010.
Web.
Osso, Jr., J. A., Barrio, G., Dias, C. R.B.R., Brambilla, T. P., Dantas, D. M., Suzuki, K. N., Barboza, M. F.S., Bortoleti, E., Fukumori, N. T., & Mengatti, J.
Country report: Brazil. Development of Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide Therapy at IPEN-CNEN/SP.
IAEA.
Osso, Jr., J. A., Barrio, G., Dias, C. R.B.R., Brambilla, T. P., Dantas, D. M., Suzuki, K. N., Barboza, M. F.S., Bortoleti, E., Fukumori, N. T., and Mengatti, J.
2010.
"Country report: Brazil. Development of Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide Therapy at IPEN-CNEN/SP."
IAEA.
@misc{etde_22270089,
title = {Country report: Brazil. Development of Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide Therapy at IPEN-CNEN/SP}
author = {Osso, Jr., J. A., Barrio, G., Dias, C. R.B.R., Brambilla, T. P., Dantas, D. M., Suzuki, K. N., Barboza, M. F.S., Bortoleti, E., Fukumori, N. T., and Mengatti, J.}
abstractNote = {The overall objective of this CRP is to develop radiopharmaceuticals for targeted therapy using {sup 188}Re and {sup 90}Y and to study the performance of generators with long lived parent radionuclides as well as to validate the QC control procedures for estimating the purity of generator eluents. The CRP is expected to enhance the capability in production of {sup 90}Y and {sup 188}Re radiopharmaceuticals to meet the increasing demand of therapeutic products for clinical applications, in particular in Brazil. In this period efforts were made towards the assembling of {sup 90}Sr-{sup 90}Y generators, quality control of {sup 90}Y, the labelling of DMSA(V) and anti-CD20 with {sup 188}Re and the labelling of Hydroxiapatite(HA) with {sup 90}Y. (author)}
place = {IAEA}
year = {2010}
month = {Jul}
}
title = {Country report: Brazil. Development of Radiopharmaceuticals Based on {sup 188}Re and {sup 90}Y for Radionuclide Therapy at IPEN-CNEN/SP}
author = {Osso, Jr., J. A., Barrio, G., Dias, C. R.B.R., Brambilla, T. P., Dantas, D. M., Suzuki, K. N., Barboza, M. F.S., Bortoleti, E., Fukumori, N. T., and Mengatti, J.}
abstractNote = {The overall objective of this CRP is to develop radiopharmaceuticals for targeted therapy using {sup 188}Re and {sup 90}Y and to study the performance of generators with long lived parent radionuclides as well as to validate the QC control procedures for estimating the purity of generator eluents. The CRP is expected to enhance the capability in production of {sup 90}Y and {sup 188}Re radiopharmaceuticals to meet the increasing demand of therapeutic products for clinical applications, in particular in Brazil. In this period efforts were made towards the assembling of {sup 90}Sr-{sup 90}Y generators, quality control of {sup 90}Y, the labelling of DMSA(V) and anti-CD20 with {sup 188}Re and the labelling of Hydroxiapatite(HA) with {sup 90}Y. (author)}
place = {IAEA}
year = {2010}
month = {Jul}
}